Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Regional scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Erythropoietin Drugs Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping for Type, 2022
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing incidence of chronic diseases
3.3.1.2 Off-label use of Erythropoiesis stimulating agents (ESAs)
3.3.2 Market Restraint Analysis
3.3.2.1 Patent expiration of branded drugs
3.4 Market Analysis Tools
3.4.1 Industry Analysis: Porter’s Five Forces
3.4.1.1 Threat of new entrants: Moderate
3.4.1.2 Bargaining power of buyers: Moderate
3.4.1.3 Competitive rivalry: High
3.4.1.4 Threat of substitutes: High
3.4.1.5 Bargaining power of suppliers: Low
3.4.2 Industry Analysis: PESTEL
3.4.2.1 Political & Legal
3.4.2.2 Economical
3.4.2.3 Technological
3.5 Pipeline Analysis
Chapter 4 Erythropoietin Drugs Market: Segment Analysis, by Type, 2018 – 2030 (USD Million)
4.1 Erythropoietin Drugs Market: Type Movement Analysis
4.1.1 Biologics
4.1.1.1 Biologics Market Estimates and Forecast, 2018 – 2030 (USD Million)
4.1.2 Biosimilars
4.1.2.1 Biosimilars Market Estimates and Forecast, 2018 – 2030 (USD Million)
Chapter 5 Erythropoietin Drugs Market: Segment Analysis, by Product, 2018 – 2030 (USD Million)
5.1 Erythropoietin Drugs Market: Product Movement Analysis
5.1.1 Erythropoietin
5.1.1.1 Erythropoietin Market Estimates and Forecast, 2018 – 2030 (USD Million)
5.1.2 Darbepoetin-alfa
5.1.2.1 Darbepoetin Market Estimates and Forecast, 2018 – 20302018 – 2030 (USD Million)
Chapter 6 Erythropoietin Drugs Market: Segment Analysis, by Application, 2018 – 2030 (USD Million)
6.1 Erythropoietin Drugs Market: Application Movement Analysis
6.1.1 Cancer
6.1.1.1 Cancer Market Estimates and Forecast, 2018 – 20302018 – 2030 (USD Million)
6.1.2 Renal Diseases
6.1.2.1 Renal Diseases Market Estimates and Forecast, 2018 – 2030 (USD Million)
6.1.3 Neurology
6.1.3.1 Neurology Market Estimates and Forecast, 2018 – 2030 (USD Million)
6.1.4 Others
6.1.4.1 Others Market Estimates and Forecast, 2018 – 2030 (USD Million)
Chapter 7 Erythropoietin Drugs Market: Regional Estimates and Trend Analysis, by Type, Product, & Application
7.1 North America
7.1.1 SWOT Analysis
7.1.1.1 North America Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2 Europe
7.2.1 SWOT Analysis:
7.2.1.1 Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.3 UK
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 UK Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.9.7 Rest of Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3 Asia Pacific
7.3.1 SWOT Analysis:
7.3.1.1 Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.2 Japan
7.3.2.1 Key Country Dynamics
7.3.2.2 Target Disease Prevalence
7.3.2.3 Competitive Scenario
7.3.2.4 Regulatory Framework
7.3.2.5 Reimbursement Scenario
7.3.2.6 Japan Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.3 China
7.3.3.1 Key Country Dynamics
7.3.3.2 Target Disease Prevalence
7.3.3.3 Competitive Scenario
7.3.3.4 Regulatory Framework
7.3.3.5 Reimbursement Scenario
7.3.3.6 China Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.4 India
7.3.4.1 Key Country Dynamics
7.3.4.2 Target Disease Prevalence
7.3.4.3 Competitive Scenario
7.3.4.4 Regulatory Framework
7.3.4.5 Reimbursement Scenario
7.3.4.6 India Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.5 Australia
7.3.5.1 Key Country Dynamics
7.3.5.2 Target Disease Prevalence
7.3.5.3 Competitive Scenario
7.3.5.4 Regulatory Framework & Reimbursement Scenario
7.3.5.5 Australia Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.6 Thailand
7.3.6.1 Key Country Dynamics
7.3.6.2 Target Disease Prevalence
7.3.6.3 Competitive Scenario
7.3.6.4 Regulatory Framework & Reimbursement Scenario
7.3.6.5 Thailand Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.7 South Korea
7.3.7.1 Key Country Dynamics
7.3.7.2 Target Disease Prevalence
7.3.7.3 Competitive Scenario
7.3.7.4 Regulatory Framework & Reimbursement Scenario
7.3.7.5 South Korea Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.7.6 Rest of Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4 Latin America
7.4.1 SWOT Analysis:
7.4.1.1 Latin America Erythropoietin Drugs market estimates and forecasts, 2018 – 2030 (USD Million)
7.4.2 Brazil
7.4.2.1 Key Country Dynamics
7.4.2.2 Target Disease Prevalence
7.4.2.3 Competitive Scenario
7.4.2.4 Regulatory Framework
7.4.2.5 Reimbursement Scenario
7.4.2.6 Brazil Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.3 Mexico
7.4.3.1 Key Country Dynamics
7.4.3.2 Target Disease Prevalence
7.4.3.3 Competitive Scenario
7.4.3.4 Regulatory Framework
7.4.3.5 Reimbursement Scenario
7.4.3.6 Mexico Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.4 Argentina
7.4.4.1 Key Country Dynamics
7.4.4.2 Target Disease Prevalence
7.4.4.3 Competitive Scenario
7.4.4.4 Regulatory Framework
7.4.4.5 Reimbursement Scenario
7.4.4.6 Argentina Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.4.7 Rest of Latin America Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5 Middle East & Africa (MEA)
7.5.1 SWOT Analysis:
7.5.1.1 Middle East & Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.2 South Africa
7.5.2.1 Key Country Dynamics
7.5.2.2 Target Disease Prevalence
7.5.2.3 Competitive Scenario
7.5.2.4 Regulatory Framework
7.5.2.5 Reimbursement Scenario
7.5.2.6 South Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.3 Saudi Arabia
7.5.3.1 Key Country Dynamics
7.5.3.2 Target Disease Prevalence
7.5.3.3 Competitive Scenario
7.5.3.4 Regulatory Framework
7.5.3.5 Reimbursement Scenario
7.5.3.6 Saudi Arabia Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.4 UAE
7.5.4.1 Key Country Dynamics
7.5.4.2 Target Disease Prevalence
7.5.4.3 Competitive Scenario
7.5.4.4 Regulatory Framework
7.5.4.5 Reimbursement Scenario
7.5.4.6 UAE Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.5 Kuwait
7.5.5.1 Key Country Dynamics
7.5.5.2 Target Disease Prevalence
7.5.5.3 Competitive Scenario
7.5.5.4 Regulatory Framework
7.5.5.5 Reimbursement Scenario
7.5.5.6 Kuwait Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.5.7 Rest of MEA Erythropoietin Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 New Product Launch
8.1.2 Merger and Acquisition
8.1.3 Licensing Agreements
8.1.4 Conferences and Campaigns
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of Key Distributors and Channel Partners
8.3.2 Key Customers
8.4 Public Companies
8.4.1 Key Company Market Share Analysis, 2022
8.4.2 Company Market Position Analysis
8.4.3 Heat Map Analysis
8.4.4 Competitive Dashboard Analysis
8.4.4.1 Market Differentiators
8.5 Private Companies
8.5.1 List of Key Emerging Companies
8.5.2 Regional Network Map
8.6 Company Profiles
8.6.1. Johnson & Johnson Services, Inc.
8.6.1.1 Company Overview
8.6.1.2 Financial Performance
8.6.1.3 Product Benchmarking
8.6.1.4 Strategic Initiatives
8.6.2 Novartis AG
8.6.2.1 Company Overview
8.6.2.2 Financial Performance
8.6.2.3 Product Benchmarking
8.6.2.4 Strategic Initiatives
8.6.3 Teva Pharmaceutical Industries Ltd.
8.6.3.1 Company Overview
8.6.3.2 Financial Performance
8.6.3.3 Product Benchmarking
8.6.3.4 Strategic Initiatives
8.6.4 Amgen, Inc.
8.6.4.1 Company Overview
8.6.4.2 Financial Performance
8.6.4.3 Product Benchmarking
8.6.4.4 Strategic Initiatives
8.6.5 F. Hoffmann-La Roche Ltd.
8.6.5.1 Company Overview
8.6.5.2 Financial Performance
8.6.5.3 Product Benchmarking
8.6.5.4 Strategic Initiatives
8.6.6 LG Chem
8.6.6.1 Company Overview
8.6.6.2 Financial Performance
8.6.6.3 Product Benchmarking
8.6.6.4 Strategic Initiatives
8.6.7 Biocon
8.6.7.1 Company Overview
8.6.7.2 Financial Performance
8.6.7.3 Product Benchmarking
8.6.7.4 Strategic Initiatives
8.6.8 Intas Pharmaceuticals Ltd.
8.6.8.1 Company Overview
8.6.8.2 Financial Performance
8.6.8.3 Product Benchmarking
8.6.8.4 Strategic Initiatives
8.6.9 Sun Pharmaceutical Industries Ltd.
8.6.8.1 Company Overview
8.6.9.2 Financial Performance
8.6.9.3 Product Benchmarking
8.6.9.4 Strategic Initiatives
8.6.10 Dr. Reddy’s Laboratories Ltd
8.6.10.1 Company Overview
8.6.10.2 Product Benchmarking
8.6.10.3 Strategic Initiatives